Autoimmune Diseases
Autoimmune diseases occur when the immune system mistakenly attacks healthy tissues, leading to chronic inflammation, pain, and organ damage. At JCRC-ABT CellGene Innovations, we offer advanced therapies, including MSC-based stem cell treatments and bone marrow transplants, to help modulate immune responses, reduce inflammation, and repair damaged tissues.
What Are Autoimmune Diseases?
Autoimmune diseases are a group of conditions where the immune system, which typically defends against harmful invaders, becomes overactive and attacks the body’s own cells. Common examples include rheumatoid arthritis, lupus, and inflammatory bowel disease.
These diseases often lead to persistent symptoms like joint pain, fatigue, and tissue damage, significantly impacting daily life. Causes can include genetic predisposition, environmental triggers, and hormonal factors. While traditional treatments focus on suppressing immune activity, our therapies aim to restore immune balance and promote tissue repair for long-term improvement.
Benefits of Our Treatments for Autoimmune Diseases
Immune Modulation
MSC-based therapies help regulate the immune system, reducing its attack on healthy tissues while maintaining the body’s ability to fight infections.
Tissue Repair and Regeneration
Stem cells promote the repair of damaged tissues, such as cartilage in rheumatoid arthritis or skin in lupus, helping restore functionality.
Targeted Immune Support
Bone marrow transplants replace malfunctioning immune cells with healthy ones, effectively resetting the immune system in severe cases.
Reduced Dependency on Long-Term Medications
By addressing the root causes, these therapies minimize the need for prolonged use of immunosuppressive drugs, reducing side effects.
Why Choose JCRC-ABT CellGene Innovations?
Personalized Care, Proven Expertise
At JCRC-ABT CellGene Innovations, we specialize in regenerative therapies that go beyond symptom management to target the underlying causes of autoimmune diseases. With personalized treatment plans and a focus on long-term outcomes, we help you reclaim your health and quality of life.
1. What autoimmune diseases can be treated at JCRC-ABT?
We treat a variety of autoimmune conditions, including rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease.
2. How do MSC-based therapies work for autoimmune diseases?
MSCs help regulate overactive immune responses while repairing damaged tissues, reducing inflammation, and promoting long-term remission.
3. Are regenerative therapies a safe alternative to surgery?
Bone marrow transplants are typically recommended for severe or refractory autoimmune diseases where conventional treatments have been ineffective.
4. Can these therapies cure autoimmune diseases?
While there is no universal cure for autoimmune diseases, our therapies aim to reduce symptoms, repair damage, and promote sustained remission.
5. How long does it take to see results from these treatments?
Some patients notice improvements within weeks, while others may require several months to experience significant benefits, depending on the condition and therapy.
Achievements
Case Studies
Acute Lymphoblastic Leukemia (ALL)
A study in Blood highlighted the success of CAR-T cell therapy (tisagenlecleucel) in pediatric and young adult patients with relapsed/refractory ALL. Over 80% achieved complete remission within one month of treatment, with sustained responses observed in more than 50% at 12 months.
Non-Small Cell Lung Cancer (NSCLC)
Research published in Nature showed that combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) significantly improved progression-free survival in advanced NSCLC patients. The combination therapy demonstrated a 36% reduction in disease progression risk compared to chemotherapy.
Melanoma
A pivotal study in The New England Journal of Medicine demonstrated the efficacy of immune checkpoint inhibitors like pembrolizumab (anti-PD-1) in advanced melanoma. Patients experienced a 5-year overall survival rate of 43%, with durable tumor regression and manageable side effects, marking a breakthrough in melanoma treatment.
Cystic Fibrosis
A trial targeting CFTR gene mutations delivered via aerosolized vectors showed improved pulmonary function in patients with cystic fibrosis. Published in The Lancet Respiratory Medicine, the therapy reduced hospitalizations and improved quality of life metrics over 12 months.
Hemophilia B
Gene therapy using an AAV vector to deliver the FIX gene resulted in sustained Factor IX production in patients. A landmark study in Blood reported a significant reduction in bleeding episodes and factor replacement therapy use, lasting up to 5 years.
Leber’s Congenital Amaurosis (LCA)
The gene therapy Luxturna restored partial vision in patients with RPE65 gene mutations. Clinical trials demonstrated improved light sensitivity and navigation abilities, with effects persisting for over three years.
